The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
-
BUSINESS Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
-
REGULATORY Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
-
REGULATORY Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
-
REGULATORY Council Approves 80 Development Requests from 2nd Round
March 27, 2012
-
BUSINESS Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
-
BUSINESS Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
-
BUSINESS Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
-
BUSINESS Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
-
REGULATORY Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
-
ORGANIZATION Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
-
BUSINESS Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
-
BUSINESS Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
-
ORGANIZATION JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
-
BUSINESS Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
-
BUSINESS Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
-
REGULATORY Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
-
BUSINESS 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
-
BUSINESS Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…